(Reuters) – British pharmaceutical giant GSK said on Wednesday it will cap out-of-pocket costs at $35 per month for all its inhaled asthma and chronic lung disease medicines for eligible patients in the United States, following similar moves by two of its rivals.
(Reporting by Leroy Leo in Bengaluru)
